ACRV Insider Trading
Insider Ownership Percentage: 8.50%
Insider Buying (Last 12 Months): $20,000,500.00
Insider Selling (Last 12 Months): $0.00
Acrivon Therapeutics Share Price & Price History
Current Price: $6.02
Price Change: ▼ Price Decrease of -0.49 (-7.53%)
As of 02/7/2025 05:00 PM ET
Acrivon Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/11/2024 | Perceptive Advisors Llc | Major Shareholder | Buy | 2,353,000 | $8.50 | $20,000,500.00 | 5,360,858 | |
6/26/2023 | Ltd Chione | Major Shareholder | Sell | 16 | $12.93 | $206.88 | 3,848,632 | |
6/14/2023 | Ltd Chione | Major Shareholder | Sell | 893 | $12.13 | $10,832.09 | 3,850,704 | |
6/12/2023 | Ltd Chione | Major Shareholder | Sell | 2,000 | $12.34 | $24,680.00 | 3,854,597 | |
11/17/2022 | Ltd Chione | Major Shareholder | Buy | 400,000 | $12.50 | $5,000,000.00 | 3,856,597 | |
11/17/2022 | Ra Capital Management, L.P. | Director | Buy | 3,389,500 | $12.50 | $42,368,750.00 | 4,384,206 | |
Acrivon Therapeutics Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
2/6/2025 | Charles Schwab Investment Management Inc. | 113,840 | $0.69M | 0.0% | -2.1% | 0.366% |  |
2/4/2025 | Bank of New York Mellon Corp | 27,635 | $0.17M | 0.0% | -6.4% | 0.089% |  |
1/24/2025 | China Universal Asset Management Co. Ltd. | 6,602 | $40K | 0.0% | N/A | 0.021% |  |
12/26/2024 | JPMorgan Chase & Co. | 33,991 | $0.24M | 0.0% | +548.3% | 0.109% |  |
12/13/2024 | Exome Asset Management LLC | 116,757 | $0.82M | 0.5% | N/A | 0.375% |  |
11/19/2024 | Barclays PLC | 33,306 | $0.23M | 0.0% | +51.2% | 0.107% |  |
11/16/2024 | Geode Capital Management LLC | 302,103 | $2.12M | 0.0% | -2.0% | 0.975% |  |
11/15/2024 | Barclays PLC | 33,306 | $0.23M | 0.0% | +51.2% | 0.108% |  |
11/15/2024 | State Street Corp | 225,896 | $1.58M | 0.0% | +26.4% | 0.729% |  |
11/12/2024 | Charles Schwab Investment Management Inc. | 116,253 | $0.81M | 0.0% | -19.2% | 0.375% |  |
10/10/2024 | Exchange Traded Concepts LLC | 20,348 | $0.14M | 0.0% | -52.5% | 0.066% |  |
8/16/2024 | Perceptive Advisors LLC | 5,360,858 | $31.09M | 0.7% | +78.2% | 17.362% |  |
8/14/2024 | Marshall Wace LLP | 948,866 | $5.50M | 0.0% | +58.8% | 3.073% |  |
8/13/2024 | Sands Capital Ventures LLC | 2,122,605 | $12.31M | 4.1% | +28.4% | 6.874% |  |
8/12/2024 | XTX Topco Ltd | 10,493 | $61K | 0.0% | N/A | 0.034% |  |
8/9/2024 | Renaissance Technologies LLC | 54,500 | $0.32M | 0.0% | -46.9% | 0.177% |  |
8/9/2024 | Dimensional Fund Advisors LP | 10,066 | $58K | 0.0% | N/A | 0.033% |  |
8/1/2024 | Rhumbline Advisers | 16,209 | $94K | 0.0% | +48.9% | 0.052% |  |
7/26/2024 | Bank of New York Mellon Corp | 36,632 | $0.21M | 0.0% | +50.1% | 0.119% |  |
5/15/2024 | Baker BROS. Advisors LP | 52,885 | $0.38M | 0.0% | N/A | 0.234% |  |
5/14/2024 | American International Group Inc. | 6,016 | $43K | 0.0% | +39.2% | 0.027% |  |
5/10/2024 | Vanguard Group Inc. | 507,185 | $3.63M | 0.0% | +6.6% | 2.241% |  |
1/5/2024 | Exchange Traded Concepts LLC | 13,289 | $65K | 0.0% | +34.0% | 0.060% |  |
11/13/2023 | Federated Hermes Inc. | 226,375 | $2.16M | 0.0% | -25.6% | 1.020% |  |
9/21/2023 | Barclays PLC | 14,263 | $0.18M | 0.0% | -16.0% | 0.065% |  |
8/10/2023 | AAF Wealth Management LLC | 10,678 | $0.14M | 0.1% | N/A | 0.049% |  |
7/20/2023 | Exchange Traded Concepts LLC | 11,709 | $0.15M | 0.0% | N/A | 0.053% |  |
5/8/2023 | Federated Hermes Inc. | 613,625 | $7.79M | 0.0% | -25.5% | 2.798% |  |
2/16/2023 | HealthCor Management L.P. | 284,201 | $3.27M | 3.0% | N/A | 1.360% |  |
2/14/2023 | RA Capital Management L.P. | 4,810,508 | $55.42M | 1.1% | N/A | 23.028% |  |
2/13/2023 | Sands Capital Ventures LLC | 1,652,605 | $19.04M | 5.2% | N/A | 7.913% |  |
2/10/2023 | NEA Management Company LLC | 481,677 | $4.44M | 0.2% | N/A | 2.306% |  |
2/1/2023 | Bank of Montreal Can | 42,444 | $0.55M | 0.0% | N/A | 0.203% |  |
Data available starting January 2016
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Read More on Acrivon Therapeutics
Volume
31,865 shs
Average Volume
68,657 shs
Market Capitalization
$187.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.77
Who are the company insiders with the largest holdings of Acrivon Therapeutics?
Who are the major institutional investors of Acrivon Therapeutics?
Which major investors are selling Acrivon Therapeutics stock?
In the previous quarter, ACRV stock was sold by these institutional investors:
- Charles Schwab Investment Management Inc.
- Bank of New York Mellon Corp
Which major investors are buying Acrivon Therapeutics stock?
In the previous quarter, ACRV stock was bought by institutional investors including:
- China Universal Asset Management Co. Ltd.